Namitecan is a potent topoisomerase I inhibitor, with antitumor property. In Vitro Namitecan and cetuximab cooperate in inhibiting EGFR expression. Namitecan induces a dose-dependent decrease in EGFR expression in the different cell lines. ST1968 induces a comparable level of apoptosis in A431 and A431/TPT cells with IC 50 of 0.21 and 0.29 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Namitecan (10 mg/kg) in combination with cetuximab (1 mg/mouse) induces synergistic antitumor effects in SCC models as a function of EGFR gene copy number . ST1968 (25 mg/kg) causes acceptable body weight loss and no toxic deaths. ST1968 produces a 100% complete response rate in the mice bearing the A431 tumor, and retains a relevant activity in the topotecan-resistant tumor. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Topoisomerase I